clorazepate dipotassium has been researched along with ro13-9904 in 1 studies
Studies (clorazepate dipotassium) | Trials (clorazepate dipotassium) | Recent Studies (post-2010) (clorazepate dipotassium) | Studies (ro13-9904) | Trials (ro13-9904) | Recent Studies (post-2010) (ro13-9904) |
---|---|---|---|---|---|
325 | 90 | 11 | 6,815 | 798 | 2,755 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Capasso, A; Cavallo, F; Ding, Z; Raffa, RB; Rawls, SM | 1 |
1 other study(ies) available for clorazepate dipotassium and ro13-9904
Article | Year |
---|---|
The beta-lactam antibiotic ceftriaxone inhibits physical dependence and abstinence-induced withdrawal from cocaine, amphetamine, methamphetamine, and clorazepate in planarians.
Topics: Amphetamine; Amphetamine-Related Disorders; Animals; Anti-Bacterial Agents; Ceftriaxone; Clorazepate Dipotassium; Cocaine; Cocaine-Related Disorders; Dose-Response Relationship, Drug; Excitatory Amino Acid Transporter 2; Methamphetamine; Models, Animal; Motor Activity; Planarians; Substance Withdrawal Syndrome; Substance-Related Disorders; Time Factors | 2008 |